As of 2025-05-20, the Intrinsic Value of Capstone Therapeutics Corp (CAPS) is -3.46 USD. This CAPS valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.09 USD, the upside of Capstone Therapeutics Corp is -265.76%.
Based on its market price of 2.09 USD and our intrinsic valuation, Capstone Therapeutics Corp (CAPS) is overvalued by 265.76%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.46 - -3.46 | -3.46 | -265.76% |
| DDM - Stable | (8.75) - (58.43) | (33.59) | -1707.3% |
| DDM - Multi | (4.66) - (24.67) | (7.89) | -477.3% |
| Market Cap (mil) | 10.85 |
| Beta | 0.48 |
| Outstanding shares (mil) | 5.19 |
| Enterprise Value (mil) | 13.86 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.31% |
| Cost of Debt | 5.00% |
| WACC | 6.80% |